Logo image of NKTX

NKARTA INC (NKTX) Stock Fundamental Analysis

NASDAQ:NKTX - Nasdaq - US65487U1088 - Common Stock - Currency: USD

1.82  +0.01 (+0.55%)

After market: 1.82 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NKTX. NKTX was compared to 557 industry peers in the Biotechnology industry. NKTX has a great financial health rating, but its profitability evaluates not so good. NKTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NKTX has reported negative net income.
In the past year NKTX has reported a negative cash flow from operations.
In the past 5 years NKTX always reported negative net income.
NKTX had a negative operating cash flow in each of the past 5 years.
NKTX Yearly Net Income VS EBIT VS OCF VS FCFNKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

NKTX's Return On Assets of -23.64% is fine compared to the rest of the industry. NKTX outperforms 75.40% of its industry peers.
The Return On Equity of NKTX (-29.37%) is better than 78.64% of its industry peers.
Industry RankSector Rank
ROA -23.64%
ROE -29.37%
ROIC N/A
ROA(3y)-25.65%
ROA(5y)-27.09%
ROE(3y)-33.49%
ROE(5y)-32.64%
ROIC(3y)N/A
ROIC(5y)N/A
NKTX Yearly ROA, ROE, ROICNKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

NKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NKTX Yearly Profit, Operating, Gross MarginsNKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for NKTX has been increased compared to 1 year ago.
NKTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NKTX Yearly Shares OutstandingNKTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NKTX Yearly Total Debt VS Total AssetsNKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -1.15, we must say that NKTX is in the distress zone and has some risk of bankruptcy.
NKTX's Altman-Z score of -1.15 is in line compared to the rest of the industry. NKTX outperforms 59.25% of its industry peers.
There is no outstanding debt for NKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.15
ROIC/WACCN/A
WACCN/A
NKTX Yearly LT Debt VS Equity VS FCFNKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

NKTX has a Current Ratio of 14.48. This indicates that NKTX is financially healthy and has no problem in meeting its short term obligations.
NKTX's Current ratio of 14.48 is amongst the best of the industry. NKTX outperforms 87.07% of its industry peers.
A Quick Ratio of 14.48 indicates that NKTX has no problem at all paying its short term obligations.
NKTX's Quick ratio of 14.48 is amongst the best of the industry. NKTX outperforms 87.07% of its industry peers.
Industry RankSector Rank
Current Ratio 14.48
Quick Ratio 14.48
NKTX Yearly Current Assets VS Current LiabilitesNKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

NKTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.48%, which is quite impressive.
EPS 1Y (TTM)33.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.21% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.67%
EPS Next 2Y6.82%
EPS Next 3Y0.31%
EPS Next 5Y7.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NKTX Yearly Revenue VS EstimatesNKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
NKTX Yearly EPS VS EstimatesNKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NKTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTX Price Earnings VS Forward Price EarningsNKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTX Per share dataNKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.82%
EPS Next 3Y0.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NKTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NKARTA INC

NASDAQ:NKTX (6/18/2025, 8:12:45 PM)

After market: 1.82 0 (0%)

1.82

+0.01 (+0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners90.6%
Inst Owner Change-2.35%
Ins Owners0.46%
Ins Owner Change8.16%
Market Cap129.15M
Analysts83.08
Price Target13.46 (639.56%)
Short Float %10.61%
Short Ratio11.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.54%
Min EPS beat(2)4.19%
Max EPS beat(2)16.89%
EPS beat(4)3
Avg EPS beat(4)10.56%
Min EPS beat(4)-4.75%
Max EPS beat(4)25.93%
EPS beat(8)6
Avg EPS beat(8)10.47%
EPS beat(12)8
Avg EPS beat(12)8.17%
EPS beat(16)9
Avg EPS beat(16)6.83%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.58%
PT rev (3m)-4.58%
EPS NQ rev (1m)-0.47%
EPS NQ rev (3m)15.88%
EPS NY rev (1m)0%
EPS NY rev (3m)18.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS0
BVpS5.34
TBVpS5.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.64%
ROE -29.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.65%
ROA(5y)-27.09%
ROE(3y)-33.49%
ROE(5y)-32.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.48
Quick Ratio 14.48
Altman-Z -1.15
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)770.74%
Cap/Depr(5y)709.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.86%
EPS Next Y9.67%
EPS Next 2Y6.82%
EPS Next 3Y0.31%
EPS Next 5Y7.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.72%
EBIT Next 3Y4.08%
EBIT Next 5Y2.85%
FCF growth 1Y4.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.58%
OCF growth 3YN/A
OCF growth 5YN/A